Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 44 Polycystic Ovary Syndrome 10 Breast Diseases 4 Advanced Breast Cancer 4 Infertility 3 Recurrence 2 Ovarian Neoplasms 2 Neoplasms 2 Neoplasm Metastasis 2 Infertility, Female 2 is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients. 1 Vitamin D Deficiency 1 Uterine Cervical Neoplasms 1 Solid Tumor 1 Pathologic Processes 1 Obesity 1 Myofibroma 1 Locally Advanced Breast Cancer 1 Hypoxia 1 Hydatidiform Mole 1 HER2+ Breast Cancer 1 Gestational Trophoblastic Disease 1 Endometrioid Endometrial Cancer 1 Endometrial Neoplasms 1 ER Positive, HER2 Negative Breast Cancer 1 Carcinoma, Lobular 1 Bulbo-Spinal Atrophy, X-Linked 1 Breast Cancer Organoids 1 Anovulation 1

Interventions

exemestane 1 cabazitaxel 1 bicalutamide 1 Letrozole 1 Histamine H2 Antagonists 1 Histamine Antagonists 1 Aromatase Inhibitors 1 Antiemetics 1 Anastrozole 1 Adrenal Cortex Hormones 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × Bulbo-Spinal Atrophy, X-Linked × Letrozole × Clear all

NCT02910050 2017-12-22

BETTER

Sun Yat-sen University

Phase 2 Unknown

Breast Neoplasms, Bulbo-Spinal Atrophy, X-Linked

Data powered by HemOnc (CC BY 4.0) Colophon ⚡